XML 40 R23.htm IDEA: XBRL DOCUMENT v3.26.1
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
12 Months Ended
Dec. 31, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Merger Transaction
The Company recorded a gain on the transaction of $2.0 billion during the year ended December 31, 2024, which consisted of the following components (in thousands):
YEAR ENDED
DECEMBER 31, 2024
Merger consideration for common stock, warrants, and stock options$1,727,687 
Book value of Amended 2020 Loans assumed by Acquirer211,315 
Book value of net assets and liabilities related to INBRX-101 assumed by Acquirer14,496 
Transaction costs paid by Acquirer68,000 
Total gain recognized$2,021,498 
Schedule of Fair Value Measurements On a Recurring Basis
Financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type are presented in the following table (in thousands):
Level 1
Level 2
Level 3
Total
December 31, 2025
Money market funds$5,870 $— $— $5,870 
Total assets measured at fair value
$5,870 $— $— $5,870 
December 31, 2024
Money market funds$5,093 $— $— $5,093 
Total assets measured at fair value
$5,093 $— $— $5,093 
Schedule of Potential Dilutive Securities Excluded from Diluted Loss Per Share
Potentially dilutive securities not included in the calculation of diluted net loss per share are as follows (in thousands):
YEAR ENDED
DECEMBER 31, 2025
Outstanding stock options3,501 
Warrants to purchase common stock141 
Total3,642 
In periods in which the Company has net income, the Company applies the treasury stock method to determine the dilutive effect of potentially dilutive securities. Potentially dilutive securities included in the diluted earnings per share are as follows (in thousands):
YEAR ENDED
DECEMBER 31, 2024
Outstanding stock options182 
Total182 
Schedule of Segment Reporting Information, by Segment
The table below summarizes the significant segment revenue and significant segment expenses which are regularly reported to and reviewed by the CODM for the purposes of making decisions regarding the allocation of resources and are reconciled to consolidated net income (loss) for the years ended December 31, 2025 and December 31, 2024 (in thousands):
YEAR ENDED
DECEMBER 31,
20252024
Segment net income (loss)
Revenue$1,300 $200 
Research and development expense
Personnel35,372 72,790 
Clinical trials35,339 47,665 
Contract manufacturing19,590 55,643 
Equipment, depreciation, and facility10,227 9,693 
Other research and development12,500 17,952 
General and administrative expense
Merger-related— 68,061 
Personnel14,481 37,649 
Other general and administrative8,816 22,195 
Other income (expense)(5,028)(2,476)
Other segment items(1)
— 2,021,498 
Other segment expenses(2)
Segment and consolidated net income (loss)$(140,055)$1,687,572 
(1) Other segment items consist of the gain on transaction from the Merger, discussed above.
(2) Other segment expenses include provision for income taxes.